Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome

Blood

Volumn 94, Issue 4, 1999, Pages 1237-1247

  Matthews, Dana C ^a   Appelbaum, Frederick R ^b   Eary, Janet F ^b   Fisher, Darrell R ^b   Durack, Lawrence D ^b   Hui, T Edmond ^b   Martin, Paul J ^b   Mitchell, David ^b   Press, Oliver W ^b   Storb, Rainer ^b   Bernstein, Irwin D ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131;

ACUTE LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG TOLERABILITY; HUMAN; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0033566795     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.4.1237     Document Type: Article

References (60)

1. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill R, McDonald G, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen J, Thomas ED: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission. A randomized trial of two irradiation regimens. Blood 76:1867, 1990
2. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Meyers J, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 77:1660, 1991
3. Redwood WR, Tom TD, Strand M: Specificity, efficacy and toxicity of radioimmunotherapy in erythroleukemic mice. Cancer Res 44:5681, 1984
4. 131I-labeled anti-T-cell antibodies. Cancer Res 46:6223, 1986
5. Macklis RM, Kaplan WD, Ferrara JL, Kinsey BM, Kassis AI, Burakoff SJ: Biodistribution studies of anti-Thy 1.2 IgM immunoconjugates: Implications for radioimmunotherapy. Int J Rad Oncol Biol Phys 15:383, 1988
6. Knox SJ, Levy R, Miller Ra, Uhland W, Schiele J, Ruehl W, Finston R, Day-Lollini P, Goris ML: Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 50:4935, 1990
7. Nourigat CL, Badger CC, Bernstein ID: Treatment of lymphoma with radiolabeled antibody: Elimination of tumor cells lacking target antigen. J Natl Cancer Inst 82:47, 1990
8. Schmidberger H, Buchsbaum DJ, Blazar BR, Everson P, Vallera DA: Radiotherapy in mice with yttrium-90-labeled anti-Lyl monoclonal antibody: Therapy of the T cell lymphoma EL4. Cancer Res 51:1883, 1991
9. van der Jagt RH, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF, Krohn KA, Bernstein ID: Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 52:89, 1992
10. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 52:6476, 1992
11. Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M: Effective alpha-particle radioimmunotherapy of murine leukemia. Cancer Res 52:5818, 1992
12. Ruble G, Wu C, Squire RA, Gansow OA, Strand M: The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int J Rad Oncol Biol Phys 34:609, 1996
13. Lenhard RE Jr, Order SE, Spunberg JJ, Asbell SO, Leibel SA: Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 3:1296, 1985
14. 131I-labeled monoclonal antibody: An Illinois Cancer Council Study. J Clin Oncol 5:562, 1987
15. 131I Lym-1. Cancer Res 50:1014s, 1990
16. Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ: A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression. J Clin Oncol 8:792, 1990
17. Parker BA, Vassos AB, Halpern SE, Miller Ra, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MR, Royston I: Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50:1022s, 1990
18. Vriesendorp HM, Herpst JM, Germack MA, Klein JL, Leichner PK, Loudenslager DM, Order SE: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease. J Clin Oncol 9:918, 1991
19. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, Burger K, Swayne LC, Belisle E, Hansen HJ, Pinsky CM: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548, 1991
20. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF, Old LJ: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478, 1991
21. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, Bernstein ID: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54:829, 1992
22. Waldmann TA, Pastan IH, Gansow OA, Junghans RP: The multichain interleukin-2 receptor: A target for immunotherapy. Ann Intern Med 116:148, 1992
23. 131I-M195/busulfan/cyclophosphamide (BU/CY) in patients with advanced/refractory myeloid malignancies. Blood 82:80a, 1993 (abstr, suppl 1)
24. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459, 1993
25. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein ID: Radiolabeled antibody therapy of B cell lymphomas with autologous bone marrow support. N Engl J Med 329:1219, 1993
26. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM, Scheinberg DA: Dose-escalation trial of M195 labeled with Iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11:294, 1993
27. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336, 1995
28. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, Top LE, Bamford R, Zaknoen S, Roessler E, Kasten-Sportes C, England R, Litou H, Johnson JA, Jackson-White T, Manns A, Hanchard B, Junghans RP, Nelson DL: Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86:4063, 1995
29. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122, 1995
30. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T, Grillo-Lopez A, Chinn P, Varns C, Ning S, Fowler S, Deb M, Becker M, Marquez C, Levy R: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457, 1996
31. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer 80:2706, 1997
32. Omary MD, Trowbridge IS, Battifora HA: Human homologue of murine T-200 glycoprotein. J Exp Med 152:842, 1980
33. Andres TL, Kadin ME: Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 79:546, 1983
34. Caldwell CW, Patterson WP, Hakami N: Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome. Leuk Res 11:103, 1987
35. Matthews DC, Badger CC, Fisher DR, Hui TE, Nourigat C, Appelbaum FR, Martin PJ, Bernstein ID: Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res 52:1228, 1992
36. Matthews DC, Appelbaum FR, Eary JF, Hui TE, Fisher DR, Martin PJ, Durack LD, Nelp WB, Press OW, Badger CC, Bernstein ID: Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood 78:1864, 1991
37. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, Fuller DJ, Davis JM, Karp JE, May WS, Rowley SD, Sensenbrenner LL, Vogelsang GB, Wingard JR: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315:141, 1986
38. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Flouroy N, Storb R, Thomas ED: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664, 1985
39. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Thomas ED, Bernstein ID: Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027, 1989
40. Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, Martin PJ, Appelbaum FR, Levy R, Brown SL, Miller Ra, Nelp WB, Bernstein ID: Imaging and treatment of B-cell lymphoma. J Nucl Med 31:1257, 1990
41. Society of Nuclear Medicine: MIRD Primer for Absorbed Dose Calculations. New York, NY, Society of Nuclear Medicine, 1988
42. Christy M, Eckerman KF: Specific Absorbed Fractions of Energy at Various Ages From Internal Photon Sources. Oak Ridge, TN, Oak Ridge National Laboratory, 1987
43. Fisher DR, Badger CC, Breitz H, Eary JF, Durham JS, Hui TE, Hill RL, Nelp WB: Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antib Immunoconj Radiopharm 4:655, 1991
44. Sgouros G: Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34:689, 1993
45. Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradly EW, Badger CC, Brill AB, Kwok CS, Stickney DR, Eckerman KF, Fisher DR, Buchsbaum DJ, Order SE: Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 3:213, 1990
46. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988
47. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
48. 131I-labeled anti-myeloid antibody in normal dogs: Effects of a "cold" antibody pretreatment dose of marrow localization. Exp Hematol 17:929, 1989
49. Down JD, Tarbell NJ, Thames HD, Mauch PM: Syngeneic and allogeneic bone marrow engraftment after total body irradiation: Dependence on dose, dose rate, and fractionation. Blood 77:661, 1991
50. Ploemacher RE, van Os R, van Beurden CA, Down JD: Murine haemopoietic stem cells with long-term engraftment and marrow repopulating ability are more resistant to gamma-radiation than are spleen colony forming cells. Int J Radiat Biol 61:489, 1992
51. Song CW, Kim TH, Khan FM, Kersey JF, Levitt SM: Radiobiological basis of total body irradiation with different dose rate and fractionation: Repair capacity of hemopoietic cells. Int J Radiat Oncol Biol Phys 7:1695, 1981
52. Storb R, Raff RF, Graham T, Appelbaum FR, Deeg HJ, Schuening FG, Sale G, Seidel K: Dose rate dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. Biol Blood Marrow Transplant (in press)
53. Uckun FM, Chandan-Langlie M, Jaszcz W, Obuz V, Waddick K, Song CW: Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia. Cancer Res 53:1431, 1993
54. Macklis RM, Beresford BA, Palayoor S, Sweeney S, Humm JL: Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys 27:643, 1993
55. Fitzgerald TJ, McKenna M, Kase K, Daugherty C, Rothstein L, Greenberger JS: Effect of x-irradiation dose rate on the clonagenic survival of human and experimental animal hematopoietic tumor cell lines: Evidence for heterogeneity. Int J Radiat Oncol Biol Phys 12:69, 1986
56. Williams JR, Zhang Y, Dillehay LE: Sensitization processes in human tumor cells during protracted irradiation: Possible exploitation in the clinic. Int J Radiat Oncol Biol Phys 24:699, 1992
57. Jurcic JG, McDevitt MR, Sgouros G, Ballangrud A, Finn RD, Geerlings MW, Humm JL, Molinet R, Apostolidis C, Larson SM, Scheinberg DA: Targeted alpha-particle therapy for myeloid leukemia: A phase I trial of bismuth-213-HuM195 (anti-CD33). Blood 90:504a, 1997 (abstr, suppl 1)
58. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission. Blood 88:142a, 1996 (abstr, suppl 1)
59. 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. Blood 93:737, 1999
60. Stabin MG: MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 27:538, 1996